CLINICAL TRIALS PROFILE FOR ZOLEDRONIC ACID

505(b)(2) Clinical Trials for ZOLEDRONIC ACID

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00145275 ↗	To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women	Completed	Novartis	Phase 3	2004-12-01	Zoledronic acid is a medicine being studied in people with low bone mass. Side effects such as headache, fever, muscle aches, and pains, may occur following the infusion. This study will investigate the use of over-the-counter medicines to improve these symptoms.

All Clinical Trials for ZOLEDRONIC ACID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00022087 ↗	Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2001-12-01	RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus calcium and vitamin D to see how well they work in preventing bone loss in women who are receiving adjuvant chemotherapy for breast cancer.
NCT00022087 ↗	Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer	Completed	Alliance for Clinical Trials in Oncology	Phase 3	2001-12-01	RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus calcium and vitamin D to see how well they work in preventing bone loss in women who are receiving adjuvant chemotherapy for breast cancer.
NCT00029224 ↗	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions	Completed	Novartis	Phase 4	2001-10-01	Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.
NCT00035997 ↗	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis	Completed	Novartis Pharmaceuticals	Phase 4	2002-04-01	The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when administered in conjunction with hormonal cancer therapy. This trial will seek to determine the effect of ZOMETA in stabilizing and increasing bone mineral density in these patients. This prospective, open-label, single arm, multicenter study will enroll approximately 200 prostate cancer patients with a history of at least one documented bone lesion documented by bone scan or radiograph. Patients must already be receiving hormone therapy and meet the following additional criteria: - 18 years of age or older - Histologically confirmed diagnoses of prostate cancer - Confirmed objective evidence of metastatic bone disease as evidenced by bone scan or radiograph - Received or will receive hormonal treatment also know as androgen deprivation therapy with an LHRH agonist or other hormonal treatments Throughout the course of this 12-month trial, patients will be identified based on the duration of established hormonal treatment at the time of enrollment. Each patients duration of participation will be up to 56 weeks including a 4 week screening, 48 week treatment and a 4 week follow up.
NCT00039104 ↗	Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2002-04-01	Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Combining zoledronate with BMS-275291 may kill more tumor cells.
NCT00046254 ↗	Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture	Completed	Novartis Pharmaceuticals	Phase 3	2002-02-01	The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.
NCT00049452 ↗	Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2001-12-01	RATIONALE: It is not yet known whether zoledronate is effective in preventing bone loss in premenopausal women who are receiving adjuvant chemotherapy after undergoing surgery for early stage breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate in preventing bone loss in premenopausal women who are receiving chemotherapy after surgery for early stage breast cancer.

Clinical Trial Conditions for ZOLEDRONIC ACID

Condition Name

Condition Name for ZOLEDRONIC ACID
Intervention	Trials
Osteoporosis	52
Breast Cancer	40
Prostate Cancer	27
Multiple Myeloma	17

Condition MeSH

Condition MeSH for ZOLEDRONIC ACID
Intervention	Trials
Osteoporosis	76
Breast Neoplasms	58
Neoplasm Metastasis	51
Prostatic Neoplasms	44

Clinical Trial Locations for ZOLEDRONIC ACID

Trials by Country

Trials by Country for ZOLEDRONIC ACID
Location	Trials
United States	856
United Kingdom	76
Canada	71
Germany	58
Australia	46

Trials by US State

Trials by US State for ZOLEDRONIC ACID
Location	Trials
California	44
New York	40
Pennsylvania	38
Florida	33
Texas	29

Clinical Trial Progress for ZOLEDRONIC ACID

Clinical Trial Phase

Clinical Trial Phase for ZOLEDRONIC ACID
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for ZOLEDRONIC ACID
Clinical Trial Phase	Trials
Completed	172
Recruiting	41
Terminated	36

Clinical Trial Sponsors for ZOLEDRONIC ACID

Sponsor Name

Sponsor Name for ZOLEDRONIC ACID
Sponsor	Trials
Novartis Pharmaceuticals	69
Novartis	48
National Cancer Institute (NCI)	22

Sponsor Type

Sponsor Type for ZOLEDRONIC ACID
Sponsor	Trials
Other	314
Industry	179
NIH	35

Last updated: May 21, 2026

Zoledronic Acid Clinical Trials Update, Market Analysis, and Exclusivity-Protected Launch Projections (US and Key Markets)

Zoledronic acid is a long-established bisphosphonate sold globally for oncology and bone-metastasis indications (notably prevention of skeletal-related events) and for bone disease indications in osteoporosis and other settings. Clinical trial activity remains focused on (1) new formulations and delivery systems, (2) combination regimens in oncology, and (3) metastatic prostate/breast/multiple myeloma supportive-care endpoints. Market growth is driven by oncology demand and expanded dosing convenience while patent and regulatory exclusivity primarily constrain true generic entry for specific salt/product platforms, not for the active ingredient as a whole.

What is zoledronic acid’s current clinical trials landscape by indication and phase?

Zoledronic acid’s clinical footprint is dominated by supportive-care studies in oncology and by comparative or adjunct studies tied to dosing, timing, and administration.

Oncology supportive care: skeletal-related events and survival-adjacent endpoints

The recurring trial objective is reducing skeletal-related events (SREs) in:

• Metastatic breast cancer
• Metastatic castration-resistant prostate cancer
• Multiple myeloma
• Other solid tumors with bone metastases

Common design patterns include randomized comparisons vs placebo or vs alternative antiresorptives, with primary endpoints such as:

• Time to first SRE
• Proportion experiencing SRE
• Bone pain scores and opioid use
• Radiologic progression markers in some protocols

Combination trials: how zoledronic acid is being paired

Trials frequently test zoledronic acid with systemic anticancer regimens (chemotherapy, targeted agents, or immunotherapies) under the supportive-care umbrella. These studies are generally oriented to:

• Safety and tolerability (renal, osteonecrosis risk)
• Efficacy signals on SRE reduction
• Timing relative to cancer therapy cycles

Formulation and delivery: why trials still run

Even with an established active ingredient, trials persist for:

• Alternative infusion durations and administration workflows
• Modified-release or device-assisted delivery concepts
• Stability, compatibility, and usability studies that can support product differentiation and payer acceptance

Regulatory-enabling studies

In parallel with interventional trials, the strategy for generic and biosimilar-adjacent competition (where applicable) often relies on:

• Bioequivalence where feasible
• Bridge studies for new dosage forms or presentation formats
• Clinical pharmacology work focused on infusion handling and patient safety

Which indications have the most ongoing or recent zoledronic acid trial activity?

Across global registries, the highest density of studies typically aligns with:

1. Oncology bone metastases (SRE prevention)
2. Multiple myeloma supportive care
3. Osteoporosis-related indications (less consistently interventional for brand differentiation, more often for comparative or post-marketing follow-on products)
4. Paget’s disease (often tied to historical regimens and periodic comparative evaluations)

When do zoledronic acid patents or exclusivity periods expire, and what does that mean for generics?

Zoledronic acid’s active ingredient patent coverage has long since matured in most major jurisdictions. Practical exclusivity typically comes from:

• Product-specific patents (process, formulation, device, or method-of-use tied to specific label claims)
• Regulatory exclusivity (data exclusivity, when applicable for a specific NDA or supplemental application)
• Exclusivity attached to a particular brand’s regulatory pathway, not to the molecule globally

What loses exclusivity first in practice

For commercial entry, the binding constraints are usually:

• Orange Book “listed drug” exclusivity for specific NDA/BLA products in the US
• Dossier protection for specific product presentations and label-comparable claims
• Litigation settlements impacting early launch dates for specific generic applicants

What is the Orange Book status of zoledronic acid in the US?

This requires the specific FDA “listed drug” entries and patent lists (NDA/ANDA numbers and associated expiration dates). Without those product-level identifiers, a precise Orange Book status summary cannot be produced without risking incorrect patent linkage.

What patent estate strengths or barriers exist for zoledronic acid product differentiation?

For zoledronic acid, “estate strength” is usually not about molecule-level coverage, but about:

• Product presentation (vial size, concentration)
• Manufacturing process claims (if any remain in specific families)
• Method-of-use claims tied to label language or dosing schedules
• Administration-related claims

From a litigation and freedom-to-operate perspective, the highest risk generally sits at the intersection of:

• A generic applicant seeking “label carve-in” vs “label carve-out”
• A brand maintaining claims that track dosing regimens or specific use populations

How strong is the market for zoledronic acid today by geography and segment?

Zoledronic acid is a mature, high-volume supportive-care drug. Demand is predominantly oncology-led, where prescribers rely on it for:

• Prevention of SREs in bone metastatic disease
• Supportive management in multiple myeloma care pathways

Key market drivers

• Persistent incidence of bone metastatic disease in breast and prostate cancers
• Ongoing treatment intensification in metastatic oncology that increases supportive-care touchpoints
• Clinical practice preference for established bisphosphonate regimens with familiar safety management

Key constraints

• Renal safety monitoring requirements
• Osteonecrosis of the jaw (ONJ) risk management
• Competing antiresorptives (especially other bisphosphonates and denosumab-class agents depending on label/setting)
• Biosimilar or generic competition at the product level in many markets

Which companies sell zoledronic acid and how do their portfolios shape competition?

Competition is typically structured around:

• Brand manufacturers holding specific product presentations and distribution networks
• Generic entrants in multiple regions with price pressure
• Parallel supportive-care portfolios (denosumab and other bone-targeted agents) that shift payer and guideline adoption

A company-level attribution requires product list and market-share data by region; producing that without exact sourcing risks factual errors.

How does zoledronic acid compare with denosumab and other bisphosphonates on treatment adoption?

In clinical adoption, the competitive frame is:

• Zoledronic acid: dosing convenience depends on infusion schedules, renal considerations, and long-established practice patterns
• Denosumab: often adopted when clinicians prefer it in specific settings, with monitoring frameworks distinct from bisphosphonates

Switching patterns depend on guideline positioning, payer preference, safety profile handling, and patient renal function.

What market projections are most defensible for zoledronic acid through 2030?

Without a sourced baseline revenue, volumes, and region split, defensible numeric projections cannot be stated without inventing figures. What can be stated structurally is:

Projection drivers that increase demand

• Oncology incidence growth and prolonged survival with metastatic therapies
• Continued supportive-care standardization for bone metastases
• Expanded adoption in outpatient infusion workflows where product logistics are optimized

Projection headwinds that cap pricing

• Generic substitution in many markets once product-specific exclusivity and patent barriers clear
• Margin compression from tendering and reimbursement pressure
• Therapeutic class competition in guideline-driven selection

Most likely trajectory profile

For a mature molecule, the base-case pattern in most markets is:

• Volume stability or mild growth with pricing pressure
• Earnings growth slower than volume growth, depending on generic penetration timing by region and tendering intensity

What generic entry risks exist for zoledronic acid products, and how do they change by region?

Generic entry risk is product-level. Key determinants:

• Whether a specific presentation still has enforceable patents
• Whether litigation has imposed a “no-launch” or delayed launch via settlement
• Whether the label is shared such that generics can enter without requiring label carve-outs

Region-by-region risk profiling must be tied to the exact product’s NDA/ANDA, patent families, and litigation record.

What clinical outcomes matter most in zoledronic acid trials for commercialization relevance?

Commercially meaningful endpoints in oncology supportive care:

• Time to first SRE
• Reduction in SRE incidence over defined follow-up windows
• Bone pain and analgesic use
• Safety under routine monitoring: renal function and ONJ management feasibility

Regulatory and payer reviewers respond to trial evidence aligned with the label history and real-world monitoring burden.

How to translate trial updates into launch timing and revenue exposure for stakeholders

A practical translation framework:

• If trials are formulation or administration-focused, they typically support life-cycle differentiation rather than fundamental indication expansion.
• If trials are combination regimens with label-adjacent endpoints, the impact on reimbursement can be incremental unless results support a meaningful label supplement.
• If trials are primarily comparative safety in specific populations (renal impairment strata, dental clearance adherence), the commercial effect is often adoption-focused and payer-narrative driven rather than volume-transforming.

Key takeaways

• Zoledronic acid trial activity remains anchored in oncology supportive care and product workflow differentiation rather than molecule novelty.
• Exclusivity and patent barriers, where present, are usually product- and label-specific, not active-ingredient wide.
• Commercial direction is predominantly oncology demand-led with pricing pressure from generics and therapeutic class competition.
• Numeric market projections and Orange Book status require product-level identifiers and cited baselines; without those, only structural forecasts can be stated.

FAQs

1. What endpoints do zoledronic acid trials use to support skeletal-related event claims?
2. How do renal safety and ONJ risk management influence prescribing and payer uptake for zoledronic acid?
3. Which formulation or administration changes most often drive lifecycle differentiation for zoledronic acid products?
4. How do generics typically enter zoledronic acid markets when molecule patents have expired?
5. How does zoledronic acid adoption change when switching between bisphosphonates and denosumab for bone metastases?

References

1. FDA Orange Book (Drug Products; List of Approved Drug Products with Therapeutic Equivalence Evaluations). U.S. Food and Drug Administration.
2. ClinicalTrials.gov. U.S. National Library of Medicine.
3. EMA. European Medicines Agency. Public assessment and product information resources.